BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the BioCHRIST fourth quarter 2025 conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by . After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Nick Bielder with Biochrist. Please go ahead. Good morning and welcome to Biochrist's full year 2025 corporate update and financial results conference call. Participating with me today are President and CEO Charlie Geyer, Chief Financial Officer Bob Ruggias, and Chief Development Officer Dr. Bill Sheridan. A press release and slide presentation about today's news are available on our investor relations website. Today's call may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide two of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures, against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations ...